Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CME Stock Forecast 2025-2026
$282.55
Current Price
$99.71B
Market Cap
Buy 7
Hold 7
Sell 4
Wall St Analyst Ratings
Distance to CME Price Targets
+7.9%
To High Target of $305.00
-0.9%
To Median Target of $280.00
-25.3%
To Low Target of $211.00
CME Price Momentum
+2.6%
1 Week Change
+3.0%
1 Month Change
+44.9%
1 Year Change
+21.7%
Year-to-Date Change
-2.8%
From 52W High of $290.79
+46.3%
From 52W Low of $193.17
📊 TOP ANALYST CALLS
Did CME Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CME Group is one of their latest high-conviction picks.
Latest CME Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, CME has a neutral consensus with a median price target of $280.00 (ranging from $211.00 to $305.00). The overall analyst rating is Buy (6.8/10). Currently trading at $282.55, the median forecast implies a -0.9% downside. This outlook is supported by 7 Buy, 7 Hold, and 4 Sell ratings.
The most optimistic forecast comes from Alex Kramm at UBS, projecting a 7.9% upside. Conversely, the most conservative target is provided by Kenneth Worthington at JP Morgan, suggesting a 25.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CME Analyst Ratings
7
Buy
7
Hold
4
Sell
CME Price Target Range
Low
$211.00
Average
$280.00
High
$305.00
Current: $282.55
Latest CME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 3, 2025 | Citigroup | Christopher Allen | Neutral | Maintains | $275.00 |
| Jun 4, 2025 | Oppenheimer | Owen Lau | Outperform | Maintains | $300.00 |
| Apr 25, 2025 | UBS | Alex Kramm | Buy | Maintains | $305.00 |
| Apr 24, 2025 | JP Morgan | Kenneth Worthington | Underweight | Maintains | $211.00 |
| Apr 24, 2025 | Morgan Stanley | Mike Cyprys | Overweight | Maintains | $304.00 |
| Apr 24, 2025 | Oppenheimer | Outperform | Maintains | $0.00 | |
| Apr 24, 2025 | Keefe, Bruyette & Woods | Kyle Voigt | Market Perform | Maintains | $273.00 |
| Apr 23, 2025 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $283.00 |
| Apr 11, 2025 | Oppenheimer | Owen Lau | Outperform | Maintains | $279.00 |
| Apr 8, 2025 | Morgan Stanley | Overweight | Upgrade | $0.00 | |
| Apr 8, 2025 | Piper Sandler | Patrick Moley | Overweight | Maintains | $283.00 |
| Apr 7, 2025 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $279.00 |
| Apr 3, 2025 | RBC Capital | Ashish Sabadra | Sector Perform | Reiterates | $269.00 |
| Apr 2, 2025 | B of A Securities | Craig Siegenthaler | Underperform | Maintains | $219.00 |
| Mar 10, 2025 | Raymond James | Patrick O'Shaughnessy | Outperform | Upgrade | $287.00 |
| Feb 19, 2025 | Morgan Stanley | Mike Cyprys | Equal-Weight | Maintains | $263.00 |
| Feb 14, 2025 | Keefe, Bruyette & Woods | Kyle Voigt | Market Perform | Maintains | $257.00 |
| Feb 13, 2025 | JP Morgan | Kenneth Worthington | Underweight | Maintains | $212.00 |
| Feb 13, 2025 | Barclays | Benjamin Budish | Equal-Weight | Maintains | $263.00 |
| Feb 13, 2025 | RBC Capital | Ashish Sabadra | Sector Perform | Maintains | $269.00 |
CME Group Inc. (CME) Competitors
The following stocks are similar to CME Group based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CME Group Inc. (CME) Financial Data
CME Group Inc. has a market capitalization of $99.71B with a P/E ratio of 27.9x. The company generates $6.27B in trailing twelve-month revenue with a 57.8% profit margin.
Revenue growth is +10.4% quarter-over-quarter, while maintaining an operating margin of +67.6% and return on equity of +13.4%.
Valuation Metrics
Market Cap
$99.71B
Enterprise Value
$101.60B
P/E Ratio
27.9x
PEG Ratio
26.7x
Price/Sales
15.9x
Growth & Margins
Revenue Growth (YoY)
+10.4%
Gross Margin
+87.4%
Operating Margin
+67.6%
Net Margin
+57.8%
EPS Growth
+11.8%
Financial Health
Cash/Price Ratio
+1.5%
Current Ratio
1.0x
Debt/Equity
14.0x
ROE
+13.4%
ROA
+1.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CME Group Inc. (CME) Business Model
About CME Group Inc.
What They Do
Global marketplace for derivatives and futures trading.
Business Model
CME Group Inc. operates a marketplace for trading derivatives and futures, generating revenue primarily through transaction fees and clearing services. It offers a diverse range of products that allow traders to hedge against market fluctuations, thereby facilitating risk management and price discovery.
Additional Information
CME Group's electronic trading platform, CME Globex, provides worldwide access to its services, enhancing trading efficiency. The company is integral to various sectors, including agriculture, energy, and finance, contributing to liquidity and transparency in the financial markets.
Company Information
Sector
Financial Services
Industry
Financial Data & Stock Exchanges
Employees
3,760
CEO
Mr. Terrence A. Duffy
Country
United States
IPO Year
2002
Website
www.cmegroup.comCME Group Inc. (CME) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ICE Hits 52-Week High, Trades at a Discount: How to Play the Stock
Intercontinental rides on data services growth, mortgage network strength, and strategic buyouts, though rising expenses may weigh on near-term margins.
Jun 26, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
CME Group will launch CME FX Tape+ to offer centralized reference prices and enhance FX market liquidity visibility from its CLOB marketplaces, including FX futures and EBS Market, later this year.
Why It Matters
The launch of CME FX Tape+ enhances market transparency and liquidity in FX trading, potentially impacting pricing and trading strategies for investors in currency markets.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CME Group plans to launch FTSE CoreCommodity CRB futures, pending regulatory approval. The index offers broad exposure to 19 global commodities including energy and metals.
Why It Matters
CME Group's launch of FTSE CoreCommodity CRB futures could enhance liquidity and trading opportunities in commodities, impacting pricing and investment strategies in the sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bitcoin has surpassed $105K following a ceasefire, prompting interest in crypto-centric stocks like CME, ACN, V, and PYPL, which may have upside potential.
Why It Matters
Bitcoin's rebound signals renewed investor confidence in crypto, potentially boosting related stocks like CME, ACN, V, and PYPL, which may see increased demand and higher valuations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CME Group Inc. will release its Q2 2025 earnings on July 23, 2025, before market opening, with highlights available on its website at 6:00 a.m.
Why It Matters
CME Group's upcoming earnings announcement could influence stock prices and investor sentiment, signaling financial performance and potential market trends.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CME Group plans to launch E-Mini S&P BMV IPC Index futures on August 18, pending regulatory approval, offering exposure to Mexico's main equity index.
Why It Matters
The launch of E-mini S&P BMV IPC Index futures provides investors with new tools to hedge and speculate on Mexico's equity market, enhancing market liquidity and investment strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Bitcoin remains above $100K amid global tensions. CME, Visa, and PayPal are identified as potential crypto investments with growth prospects by 2025.
Why It Matters
Bitcoin's stability above $100K signals confidence in crypto amid global tensions, while CME, Visa, and PayPal's involvement suggests potential growth opportunities in the crypto market by 2025.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About CME Stock
What is CME Group Inc.'s (CME) stock forecast for 2026?
Based on our analysis of 29 Wall Street analysts, CME Group Inc. (CME) has a median price target of $280.00. The highest price target is $305.00 and the lowest is $211.00.
Is CME stock a good investment in 2026?
According to current analyst ratings, CME has 7 Buy ratings, 7 Hold ratings, and 4 Sell ratings. The stock is currently trading at $282.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CME stock?
Wall Street analysts predict CME stock could reach $280.00 in the next 12 months. This represents a -0.9% decrease from the current price of $282.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CME Group Inc.'s business model?
CME Group Inc. operates a marketplace for trading derivatives and futures, generating revenue primarily through transaction fees and clearing services. It offers a diverse range of products that allow traders to hedge against market fluctuations, thereby facilitating risk management and price discovery.
What is the highest forecasted price for CME CME Group Inc.?
The highest price target for CME is $305.00 from Alex Kramm at UBS, which represents a 7.9% increase from the current price of $282.55.
What is the lowest forecasted price for CME CME Group Inc.?
The lowest price target for CME is $211.00 from Kenneth Worthington at JP Morgan, which represents a -25.3% decrease from the current price of $282.55.
What is the overall CME consensus from analysts for CME Group Inc.?
The overall analyst consensus for CME is neutral. Out of 29 Wall Street analysts, 7 rate it as Buy, 7 as Hold, and 4 as Sell, with a median price target of $280.00.
How accurate are CME stock price projections?
Stock price projections, including those for CME Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 4:21 AM UTC